Every 10-Q that Cigna Group (CI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CI filings page.
The Cigna Group reported Q2 2026 results with total revenues of $71,668 million, up from $67,178 million a year earlier, driven mainly by higher Evernorth Health Services pharmacy revenues. Shareholders' net income was $1,660 million, and diluted EPS was $6.29, both above Q2 2025.
For the first half of 2026, revenues reached $140,162 million and shareholders' net income $3,314 million. As of June 30, 2026, the company reported $157,082 million in total assets and $42,620 million of shareholders' equity, including $6,298 million of cash and cash equivalents.
Net cash provided by operating activities was $710 million for the first six months, while the company repaid $550 million of maturing senior notes, maintained a $6,500 million undrawn revolving credit facility, and had $1,000 million of commercial paper outstanding. Cigna incurred $450 million of year-to-date strategic optimization program costs and continued returning capital through dividends and common share repurchases.
The Cigna Group reported stronger results for the quarter ended March 31, 2026, driven mainly by pharmacy operations. Total revenues rose to $68.5 billion from $65.5 billion, as pharmacy revenues increased to $54.0 billion while premiums declined after the prior-year Medicare Advantage divestiture.
Shareholders’ net income grew to $1.65 billion from $1.32 billion, with diluted EPS rising to $6.26 from $4.85. Adjusted income from operations increased to $2.06 billion (or $7.79 per diluted share) from $1.84 billion ($6.74 per share), reflecting higher contributions from both Evernorth Health Services and Cigna Healthcare.
The company continued its multi‑year Strategic Optimization Program, recording $380 million of pre‑tax charges in the quarter, mainly severance, bringing program‑to‑date costs to $1.13 billion pre‑tax. Operating cash flow was $1.13 billion, cash and cash equivalents were $7.0 billion, and long‑term debt declined to $29.4 billion. The Board declared a quarterly dividend of $1.56 per share.
The Cigna Group reported stronger Q3 2025 results. Total revenues were $69,748 million, up from $63,694 million a year ago, driven by pharmacy revenues of $56,054 million. Premiums were $9,081 million. Income from operations was $2,578 million, roughly flat year over year.
Shareholders’ net income rose to $1,868 million and diluted EPS increased to $6.98 from $2.63, aided by lower medical costs ($7,842 million vs. $9,527 million) and net investment gains ($26 million vs. a loss of $921 million). The company recorded a gain on sale of businesses and reported shareholders’ comprehensive income of $1,885 million. Cash and cash equivalents were $6,025 million and long‑term debt was $30,947 million.
Cigna completed the sale of its Medicare-related businesses to HCSC, with the purchase price increased to $4.9 billion. The company recognized a Q3 pre-tax gain of $38 million and an after-tax gain of $241 million. It received approximately $4.2 billion in cash at closing and expects about $0.6 billion in Q4 2025. In September, Cigna issued $4.5 billion of senior notes and repaid a $2.0 billion term loan used to fund its investment in Shields Health Solutions. A quarterly dividend of $1.51 per share was declared for payment on December 18, 2025.